Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a lwp-ebmt study

Archive ouverte

Bazarbachi, Ali | Boumendil, Ariane | Finel, Herve | Castagna, Luca | Dominietto, Alida | Blaise, Didier | Diez-Martin, Jose L. | Tischer, Johanna | Gulbas, Zafer | Wallet, Helene L. | Corral, Lucia L. | Mohty, Mohamad | Koc, Yener | Yakoub-Agha, Ibrahim | Schmid, Christoph | El Cheikh, Jean | Arat, Mutlu | Forcade, Edouard | Dreger, Peter | Rocha, Vanderson | Garcia, Gonzalo G. | Chalandon, Yves | Ferra, Christelle | Orvain, Corentin | Robinson, Stephen | Montoto, Silvia | Sureda, Anna

Edité par CCSD ; Wiley -

International audience. Haploidentical stem cell transplantation (haploSCT) is becoming a major transplant modality for lymphoma. To assess the effects of donor characteristics, stem cell source and conditioning on outcomes, we identified 474 adults with Hodgkin (HL; 240), peripheral T-cell (PTCL; 88), diffuse large B-cell (77), mantle cell (40) or follicular lymphoma (FL; 29), who received haploSCT with post-transplant cyclophosphamide. Median follow-up of alive patients was 32 months. On multivariate analysis, acute graft-versus-host disease (GVHD) grade 2-4 was lower with offspring donors or bone marrow cells, whereas extensive chronic GVHD was higher in partial response at haploSCT or when using sisters, haploidentical donors beyond first degree, or female donors in male patients. Progression-free survival (PFS) was better for FL, HL and PTCL, whereas overall survival (OS) was better for HL and PTCL. Complete remission at haploSCT improved PFS and OS whereas these were negatively affected by cytomegalovirus donor positive/recipient positive status. No other donor characteristics (age, gender, human leucocyte antigen mismatch, ABO incompatibility) affected PFS or OS except use of haploidentical donors beyond first degree, which negatively affected OS. PFS and OS are mostly influenced by disease status and lymphoma subtype, supporting the use of any first degree haploidentical family member as a donor.

Consulter en ligne

Suggestions

Du même auteur

Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party

Archive ouverte | Bazarbachi, Ali | CCSD

International audience. Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate. Preliminary data suggest that BV might improve outcomes after allogeneic stem cell transplantation (SCT) for Hodgkin lymphoma...

Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party

Archive ouverte | Bazarbachi, Ali | CCSD

International audience. BACKGROUND: The treatment of patients with Hodgkin lymphoma (HL) who develop disease progression after undergoing allogeneic stem cell transplantation (allo-SCT) remains challenging.METHODS: ...

Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis in HLA-matched and haploidentical donor transplants for patients with Hodgkin lymphoma: a comparative study of the LWP EBMT.: GVHD prophylaxis for patients with Hodgkin lymphoma.

Archive ouverte | Montoro, Juan | CCSD

International audience. Post-transplantation cyclophosphamide (PTCy) has emerged as a promising approach for preventing graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (allo-HS...

Chargement des enrichissements...